Most drug development is preceded by the identification of molecular targets. In our laboratory, we search for new oncogenic drivers, as well as seek to identify and characterize molecular signatures of acquired resistance to targeted therapies. Our efforts include:
- In vitro validation of newly discovered putative oncogenic drivers, as identified by next-generation sequencing
- Characterization of modes of action of putative novel oncogenes using biochemical and cellular assays
- Screens and validation of secondary mutations in known oncogenes that are likely to emerge in response to tyrosine kinase inhibition
- Analysis of compensatory signaling pathways promoting tyrosine kinase inhibitor resistance
